Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the best young stocks with huge upside potential. On October 7, Lexeo ...
Stocktwits on MSN

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the treatment of Friedreich's ataxia (FA) cardiomyopathy, scheduled to begin in the ...
Stocktwits on MSN

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Lexeo Therapeutics shares rose to an 11-month high on Tuesday following a series of analyst upgrades that have rekindled ...

Belhaven Biopharma Initiates a Pivotal Biocomparability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Nasdepi(R) vs. Epinephrine Intramuscular Injections

Application Receives FDA Authorization to Proceed RALEIGH, NORTH CAROLINA / ACCESS Newswire / October 8, 2025 / Belhaven Biopharma , a leader in developing innovative intranasal products for emergency ...
Pharmabiz

Lexeo Therapeutics reports progress in US FDA discussions for accelerated approval pathway for LX2006 in Friedreich ataxia cardiomyopathy

Lexeo Therapeutics reports progress in US FDA discussions for accelerated approval pathway for LX2006 in Friedreich ataxia cardiomyopathy: New York Saturday, October 11, 2025, 16: ...